Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma
Launched by CHALMERS UNIVERSITY OF TECHNOLOGY · Apr 4, 2016
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients referred for partial or radical nephrectomy for suspicion of renal cell carcinoma
- • Predicted life expectancy over 2 months
- • Standard imaging evaluation 12 weeks prior to inclusion
- • Planned for standard imaging within 16 weeks after start of therapy
- Exclusion Criteria:
- • Lack of proper compliance to accept continuous samplings.
About Chalmers University Of Technology
Chalmers University of Technology, located in Gothenburg, Sweden, is a leading research institution known for its innovative contributions to engineering, technology, and natural sciences. As a clinical trial sponsor, Chalmers leverages its interdisciplinary expertise and cutting-edge research capabilities to advance healthcare solutions and improve patient outcomes. The university collaborates with various stakeholders, including industry partners and healthcare providers, to conduct rigorous clinical studies that adhere to the highest ethical and scientific standards. Through its commitment to innovation and research excellence, Chalmers aims to translate scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göteborg, , Sweden
Patients applied
Trial Officials
Jens Nielsen, PhD
Principal Investigator
Chalmers University of Technology
Sven Lundstam, M.D. PhD
Principal Investigator
Sahlgrenska University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials